These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 24534455)

  • 1. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
    Martinet W; De Loof H; De Meyer GRY
    Atherosclerosis; 2014 Apr; 233(2):601-607. PubMed ID: 24534455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy.
    Martinet W; Verheye S; De Meyer GR
    Autophagy; 2007; 3(3):241-4. PubMed ID: 17224626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
    Kurdi A; Martinet W; De Meyer GRY
    Transplantation; 2018 Feb; 102(2S Suppl 1):S44-S46. PubMed ID: 28230638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective clearance of macrophages in atherosclerotic plaques by autophagy.
    Verheye S; Martinet W; Kockx MM; Knaapen MW; Salu K; Timmermans JP; Ellis JT; Kilpatrick DL; De Meyer GR
    J Am Coll Cardiol; 2007 Feb; 49(6):706-15. PubMed ID: 17291937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic effects of mTOR inhibition in atherosclerosis.
    Kurdi A; De Meyer GR; Martinet W
    Br J Clin Pharmacol; 2016 Nov; 82(5):1267-1279. PubMed ID: 26551391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia.
    Mueller MA; Beutner F; Teupser D; Ceglarek U; Thiery J
    Atherosclerosis; 2008 May; 198(1):39-48. PubMed ID: 17980369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid.
    Martinet W; Verheye S; De Meyer I; Timmermans JP; Schrijvers DM; Van Brussel I; Bult H; De Meyer GR
    Arterioscler Thromb Vasc Biol; 2012 May; 32(5):1228-35. PubMed ID: 22345170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced macrophage autophagy in atherosclerosis: for better or worse?
    Martinet W; De Meyer I; Verheye S; Schrijvers DM; Timmermans JP; De Meyer GR
    Basic Res Cardiol; 2013 Jan; 108(1):321. PubMed ID: 23233268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of miRNA-155 in carotid atherosclerotic plaques of apolipoprotein E knockout (ApoE
    Ma J; Yang S; Ma A; Pan X; Wang H; Li N; Liu S; Wu M
    Int Immunopharmacol; 2017 May; 46():70-74. PubMed ID: 28273556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase Improves Endothelial Permeability in Drug-Eluting Stents-Brief Report.
    Harari E; Guo L; Smith SL; Paek KH; Fernandez R; Sakamoto A; Mori H; Kutyna MD; Habib A; Torii S; Cornelissen A; Jinnouchi H; Gupta A; Kolodgie FD; Virmani R; Finn AV
    Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):2217-2224. PubMed ID: 30026269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque.
    Zhai C; Cheng J; Mujahid H; Wang H; Kong J; Yin Y; Li J; Zhang Y; Ji X; Chen W
    PLoS One; 2014; 9(3):e90563. PubMed ID: 24599185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.
    Kasiske BL; de Mattos A; Flechner SM; Gallon L; Meier-Kriesche HU; Weir MR; Wilkinson A
    Am J Transplant; 2008 Jul; 8(7):1384-92. PubMed ID: 18510633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice.
    Beutner F; Brendel D; Teupser D; Sass K; Baber R; Mueller M; Ceglarek U; Thiery J
    Atherosclerosis; 2012 Jun; 222(2):337-43. PubMed ID: 22446027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperglycaemia during treatment with everolimus].
    Opdam FL; Huitema AD; Beijnen JH; Schellens JH
    Ned Tijdschr Geneeskd; 2014; 158():A7544. PubMed ID: 25115206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of mTOR by lentivirus‑mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E‑deficient mice.
    Wang X; Li L; Li M; Dang X; Wan L; Wang N; Bi X; Gu C; Qiu S; Niu X; Zhu X; Wang L
    Int J Mol Med; 2013 Nov; 32(5):1215-21. PubMed ID: 24043133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
    Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
    Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis.
    Kurdi A; Roth L; Van der Veken B; Van Dam D; De Deyn PP; De Doncker M; Neels H; De Meyer GRY; Martinet W
    Vascul Pharmacol; 2019 Feb; 113():70-76. PubMed ID: 30590134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of statins on atherosclerotic plaque.
    Almeida SO; Budoff M
    Trends Cardiovasc Med; 2019 Nov; 29(8):451-455. PubMed ID: 30642643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.